The total return over the past 12 months is -6.70% vs. +16.94% for the S&P 500. So far it's up +24.36% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (6.70%) | (34.23%) | (36.88%) | N/A | N/A | N/A |
| Total Return CAGR | (6.70%) | (34.23%) | (36.88%) | N/A | N/A | N/A |
| Revenue CAGR | (100.00%) | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
INmune Bio, Inc. (INMB)
| Year | Start price | End price | INMB Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.56 | $1.94 | +24.36% | +14.51% | +9.85% |
| 2025 | $4.67 | $1.56 | (66.60%) | +17.72% | (84.32%) |
| 2024 | $11.26 | $4.67 | (58.53%) | +24.89% | (83.42%) |
| 2023 | $6.34 | $11.26 | +77.60% | +26.19% | +51.41% |
| 2022 | $10.20 | $6.34 | (37.84%) | (18.17%) | (19.67%) |
| 2021 | $17.22 | $10.20 | (40.77%) | +28.74% | (69.51%) |
| 2020 | $5.80 | $17.22 | +196.90% | +18.37% | +178.53% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
